Wayne State University

Samuel C Brooks

Jerome P Horwitz

An estrogen sulfotransferase inhibitor composition comprises a compound of the formula ##STR1## wherein R.sub.1 is F, Br, NO.sub.2, or H; R.sub.2 is F, Br, NO.sub.2, NH.sub.2, or H; R is H or alkyl of 1-4 carbon atoms; R.sub.3 is O or H.sub.2 ; and R.sub.4 is H.sub.2, O, or .alpha.-H, .beta.-OH; R.sub.5 is H.sub.2, .alpha.-H and .beta.-OH or B-H and .alpha.-OH in admixture with a pharmaceutically acceptable carrier with the proviso that R.sub.1, R.sub.2 and R.sub.3 cannot all be hydrogen and one of R.sub.1 and R.sub.2 is F.

Compositions inhibiting estrogen sulfotransferase activity

A compound of the formula ##STR1## wherein Z is alkoxy of 1-4 carbon atoms and Y is amino, inhibits the growth of murine ductal carcinoma (MXT mammary tumors). A compound wherein Z is OH and Y is nitro, administered orally, inhibits the growth of MXT mammary tumors.

Compositions inhibiting murine MXT ductal carcinoma

A compound of the formula ##STR1## wherein Z is hydrogen and Y is nitro, inhibits the growth of murine ductal carcinoma (MXT mammary tumors).

A compound of the formula ##STR1## wherein Z is alkoxy of 1-4 carbon atoms or hydroxyalkoxy of 2-4 carbon atoms and Y is nitro, inhibiting the growth of murine ductal carcinoma (MXT mammary tumors).

The present invention concerns the novel compounds having fluoro, amino, nitro or hydroxy monosubstituted at the 2- or 4- position on deoxyestrone as well as deoxyestra-17-ol. The compounds are useful as estrogen sulfotransferase inhibitors. Such estrogen sulfotransferase inhibition provides the novel use for treating a female mammal to prevent implantation of a blastocyst. Additionally, the invention concerns the novel synthesis and novel intermediates in the synthesis of the estrogen sulfotransferase inhibiting compound of the present invention.

Compounds and compositions for inhibiting estrogen sulfotransferase

An estrogen sulfotransferase inhibitor composition comprises a compound of the formula ##STR1## wherein R.sub.1 is Br, NO.sub.2, or H; R.sub.2 is Br, NO.sub.2, NH.sub.2, or H; R is H or alkyl of 1-4 carbon atoms; R.sub.3 is O or H.sub.2 ; and R.sub.4 is H.sub.2, O, or .alpha.-H, .beta.-OH, in admixture with a pharmaceutically acceptable carrier. The specificity of the invention is believed targeted to the substituent at R.sub.2 or C.sub.4 and secondarily the OR group at C.sub.3.

Growing community of inventors

Orchard Lake, MI, United States of America

Samuel C Brooks